Article: Has Wall Street Stolen $100 Trillion from the American Public? Will Donald Trump Get It Back?

Article - Media

Has Wall Street Stolen $100 Trillion from the American Public? Will Donald Trump Get It Back?

Tehran Times, May 26, 2020 – International

TEHRAN – Robert David Steele, a former Marine Corps infantry officer and CIA spy as well as an activist for Open Source Everything Engineering (OSEE), contributes regularly to Tehran Times.

Continue reading “Article: Has Wall Street Stolen $100 Trillion from the American Public? Will Donald Trump Get It Back?”

Article: Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Article - Media

Sorrento Therapeutics Analyst Says Coronavirus Antibody Cocktail One Of Few Non-Vaccine Options

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares spiked 158% Friday after the company disclosed that it has identified an antibody that demonstrated 100% inhibition of SARS-CoV-2 virus infection.

The Sorrento Analyst

H.C. Wainwright analyst Raghuram Selvaraju has a Buy rating on Sorrento with a $24 price target.

Comment: Every placement  these guys do seems to sour.  Time for an investigation?

Competing Comment: Every placement is subject to naked short selling pressure, without an investigation you cannot know for sure.  Some companies do have histories. HCWainwreight appears to be one of them.

Tip: Today’s Naked Short Selling Victim CymaBay

Tip

CymaBay Doubles After-Hours On Positive NASH Trial Update

first 1/2 hr of trading 22 MILLION shares traded everyone who is long wanted to see on this great news HURRY RUN away someone is selling a boat load of naked shorts for sure

Now the funny part the stock is down from a high of $13 to a low of $1.21 and the stories will be written today that stock is soaring or some other word saying stock has gone up enough. That’s how they get people to sell stock has doubled RUN away.

Continue reading “Tip: Today’s Naked Short Selling Victim CymaBay”

Analyst: Swayampakula Ramakanth, Ph.D.

Analyst

Dr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.

Continue reading “Analyst: Swayampakula Ramakanth, Ph.D.”

Analyst: Edward White

Analyst

Edward White is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on both the biotechnology and the specialty pharmaceutical sectors. Mr. White’s expertise covers companies operating in the oncology, immune-oncology, infectious disease, and gastrointestinal sectors. Prior to working at H.C. Wainwright, Mr. White has worked as a Wall Street Healthcare Analyst, on both the buy-side and the sell-side, since 1996. Mr. White’s previous sell-side experience includes working for Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms.

Continue reading “Analyst: Edward White”

Analyst: Doug Tsao

Analyst

Doug Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals.  Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies.

Continue reading “Analyst: Doug Tsao”

Analyst: Raghuram Selvaraju Ph.D.

Analyst

Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. Dr. Selvaraju was ranked by both the StarMine for his earnings accuracy and by The Wall Street journal’s annual Best on the Street Analyst for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A.

Continue reading “Analyst: Raghuram Selvaraju Ph.D.”

Analyst: Joseph Pantginis, Ph.D.

Analyst

Dr. Joseph Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.

Continue reading “Analyst: Joseph Pantginis, Ph.D.”